Author:
Sartore-Bianchi Andrea,Ardini Elena,Bosotti Roberta,Amatu Alessio,Valtorta Emanuele,Somaschini Alessio,Raddrizzani Laura,Palmeri Laura,Banfi Patrizia,Bonazzina Erica,Misale Sandra,Marrapese Giovanna,Leone Antonella,Alzani Rachele,Luo David,Hornby Zachary,Lim Jonathan,Veronese Silvio,Vanzulli Angelo,Bardelli Alberto,Martignoni Marcella,Davite Cristina,Galvani Arturo,Isacchi Antonella,Siena Salvatore
Publisher
Oxford University Press (OUP)
Reference12 articles.
1. The landscape of kinase fusions in cancer;Nat Commun,2014
2. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition;Mol Oncol,2014
3. Bosotti R Veronese S Somaschini A Identification of a TPM3‐TRKA rearrangement in human colon carcinoma, and development of a methodology to identify patients for treatment with TRK inhibitors. Presented at the 2013 Annual Meeting of the Associazione Italiana Oncologia Medica (AIOM), October 2013; Milan, Italy.
4. Ardini E Menichincheri M Banfi P The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models. Presented at AACR Annual Meeting, April 6-10 2013; Washington, DC.
5. Ardini E Menichincheri M Banfi P In vitro and in vivo activity of NMS-E628 against ALK mutations resitant to Xalkori. Presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, November 12–16, 2011; San Francisco, CA, USA (Abstract #A232).